The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic analysis of disitamab vedotin combined with PD-1 inhibitor first-line treatment in advanced urothelial carcinoma: A propensity score analysis.
 
Yupeng Jiang
No Relationships to Disclose
 
Chao Xu
No Relationships to Disclose
 
Wen Zou
No Relationships to Disclose
 
Minfeng Chen
No Relationships to Disclose
 
Wei He
No Relationships to Disclose
 
Yuan Li
No Relationships to Disclose
 
Yeqian Feng
No Relationships to Disclose
 
Songqing Fan
No Relationships to Disclose
 
Lin Wu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Hengrui Medicine; Innovate Biopharmaceuticals; Lilly; MSD; Pfizer; Roche China
 
Jingjing Wang
No Relationships to Disclose